Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
The curtain lifts on Veritac-2, rusfertide, and another double plenary for Astra.
Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.
The PD-1 x VEGF molecule's latest win comes from Akeso's Harmoni-6 trial.
Gilead’s TROP2 ADC prevails in Ascent-04, in first-line PD-L1-positive TNBC.
The first global pivotal trial will be in first-line triple-negative breast cancer.
A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
